Molecular pharming’s foot in the FDA’s door: Protalix’s trailblazing story

Biotechnology Letters

Volumn 37, Issue 11, 2015, Pages 2147-2150

  Mor, Tsafrir S ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Ebola; FDA approval; Gaucher s disease; Molecular pharming; Plant derived biologics

Indexed keywords

EBOLA; FDA-APPROVAL; FLAWLESS PRODUCTION; FOOD AND DRUG ADMINISTRATION; MOLECULAR PHARMING; PLANT-DERIVED BIOLOGICS; PROTEIN PHARMACEUTICALS; THERAPEUTIC PRODUCTS;

BIOTECHNOLOGY;

BIOLOGICAL PRODUCT; GLUCOSYLCERAMIDASE; PLANT PROTEIN; TALIGLUCERASE ALFA;

FOOD AND DRUG ADMINISTRATION; HUMAN; MOLECULAR FARMING; UNITED STATES;

BIOLOGICAL PRODUCTS; GLUCOSYLCERAMIDASE; HUMANS; MOLECULAR FARMING; PLANT PROTEINS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84942506505     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-015-1908-z     Document Type: Review

References (24)

1. Aggarwal S (2009) What’s fueling the biotech engine-2008. Nat Biotechnol 27:987–993
2. Aggarwal SR (2012) What’s fueling the biotech engine-2011–2012. Nat Biotechnol 30:1191–1197
3. Aviezer D, Brill-Almon E, Shaaltiel Y, Hashmueli S, Bartfeld D, Mizrachi S, Liberman Y, Freeman A, Zimran A, Galun E (2009) A plant-derived recombinant human glucocerebrosidase enzyme—a preclinical and phase I investigation. PLoS ONE 4:e4792
4. Bashaw ED, Huang SM, Cote TR, Pariser AR, Garnett CE, Burckart G, Zhang L, Men AY, Le CD, Charlab R, Gobburu JV, Lesko LJ (2011) Clinical pharmacology as a cornerstone of orphan drug development. Nat Rev Drug Discov 10:795–796
5. Bishop BM (2015) Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother 49:196–206
6. Brumshtein B, Greenblatt HM, Butters TD, Shaaltiel Y, Aviezer D, Silman I, Futerman AH, Sussman JL (2007) Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. J Biol Chem 282:29052–29058
7. Cox TM (2010) Gaucher disease: clinical profile and therapeutic developments. Biologics 4:299–313
8. Ferraz MJ, Kallemeijn WW, Mirzaian M, Herrera Moro D, Marques A, Wisse P, Boot RG, Willems LI, Overkleeft HS, Aerts JM (2014) Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses. Biochim Biophys Acta 1841:811–825
9. Hiatt A, Cafferkey R, Bowdish K (1989) Production of antibodies in transgenic plants. Nature 342:76–78
10. Ma JK, Christou P, Chikwamba R, Haydon H, Paul M, Ferrer MP, Ramalingam S, Rech E, Rybicki E, Wigdorowitz A, Yang DC, Thangaraj H (2013) Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies. Plant Biotechnol J 11:1029–1033
11. Mason HS, Lam DM, Arntzen CJ (1992) Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA 89:11745–11749
12. McCarthy M (2014) US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 349:g5488
13. Platt FM (2014) Sphingolipid lysosomal storage disorders. Nature 510:68–75
14. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47–53
15. Ratner M (2010) Pfizer stakes a claim in plant cell-made biopharmaceuticals. Nat Biotechnol 28:107–108
16. Reisch MS (2013) Protalix reaches deal with Brazil. Chem Eng News 91:11
17. Rubin EJ, Baden LR (2014) Out of Africa—caring for patients with Ebola. N Engl J Med 371:2430–2432
18. Rybicki EP (2014) Plant-based vaccines against viruses. Virol J 11:205
19. Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D (2007) Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol J 5:579–590
20. Sijmons PC, Dekker BM, Schrammeijer B, Verwoerd TC, van den Elzen PJ, Hoekema A (1990) Production of correctly processed human serum albumin in transgenic plants. Biotechnology (NY) 8:217–221
21. Stoger E, Fischer R, Moloney M, Ma JK (2014) Plant molecular pharming for the treatment of chronic and infectious diseases. Annu Rev Plant Biol 65:743–768
22. Tekoah Y, Tzaban S, Kizhner T, Hainrichson M, Gantman A, Golembo M, Aviezer D, Shaaltiel Y (2013) Glycosylation and functionality of recombinant beta-glucocerebrosidase from various production systems. Biosci Rep 33:e00071
23. Vermij P (2006) USDA approves the first plant-based vaccine. Mol Biol Evol 24:234
24. Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Munoz ET, Solorio-Meza SE, Amato D, Duran G, Giona F, Heitner R, Rosenbaum H, Giraldo P, Mehta A, Park G, Phillips M, Elstein D, Altarescu G, Szleifer M, Hashmueli S, Aviezer D (2011) Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 118:5767–5773